West Branch Capital’s Indivior Pharmaceuticals INDV Stock Holding History

West Branch Capital’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-100	Closed	-$2.14K	–	432
2024 Q1	$2.14K	Hold	100	–	–	﹤0.01%	380
2023 Q4	$1.53K	Hold	100	–	–	﹤0.01%	404
2023 Q3	$2.31K	Hold	100	–	–	﹤0.01%	384
2023 Q2	$2.38K	Buy	+100	New	+$2.29K	﹤0.01%	388

Other funds holding INDV

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

West Branch Capital's INDV Position: Q2 2024 in Review

West Branch Capital sold out of Indivior Pharmaceuticals (INDV) in Q2 2024, closing a stake of 100 shares — an estimated $2.14K sold.

West Branch Capital first reported a position in INDV in Q2 2023 and held it in 4 quarters. The position peaked at $2.38K in Q2 2023. 99 funds tracked by Wall St. Rank hold INDV as of Q2 2024.

West Branch Capital reported no remaining Indivior Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
West Branch Capital sold 100 Indivior Pharmaceuticals shares in Q2 2024, an estimated $2.14K.
West Branch Capital first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 4 quarters.
West Branch Capital's Indivior Pharmaceuticals position peaked at $2.38K in Q2 2023.
99 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2024.

Based on West Branch Capital's 13F filing for Q2 2024, filed 26 Jul 2024.